Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accord’s Teriparatide And Fresenius Kabi’s Pegfilgrastim Satisfy CHMP

Two Biosimilars And Three Generics Endorsed As Ipique Sponsor Demands Review

Executive Summary

Positive CHMP opinions recommending European marketing authorizations have been granted for Accord’s teriparatide and Fresenius Kabi’s pegfilgrastim biosimilars, while the sponsor for an ophthalmic version of bevacizumab has asked the EMA to take a second look at the rejection of its application. Three Accord generics were also endorsed by the CHMP at its January meeting.

You may also be interested in...



Fresenius Delivers First US Biosimilar Approval

Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.

Fresenius Files Tocilizumab Biosimilar With EMA

Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.

Prestige And Intas Strike International Bevacizumab Deal

Prestige Biopharma and Intas Pharmaceuticals have announced a commercialization deal for Prestige’s HD204 proposed bevacizumab biosimilar, covering a range of territories including markets in the Americas, Europe, Africa and Asia.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel